Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $7.2152W HIGH $20.46
Volume
2.83 M
Value Traded
18.63 M
Short % Float
11.28%
+2.47%Week
+10.33%1 Month
+15.5%3 Month
-0.19%6 Month
+362.92%5 Year
+17.71%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.32 B
EPS (TTM)
0.75
P/E Ratio
13.73
Ent. Value
2.38 B
Total Shares
224.03 M
Float Shares
214.67 M
Insiders
4.16%
Institutions
89.94%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ADMA Catalyst Timeline
Dated clinical, regulatory and corporate events for ADMA Biologics Inc
Catalyst Timeline
Dated clinical, regulatory & corporate events for ADMA Biologics Inc
515Total events
5Upcoming
124Tier-1 (high impact)
2013 to 2030Coverage
Upcoming catalysts 2
Event history 50
▲Label ExpansionASCENIVApprovedFDA Decision
FDA approval to expand ASCENIV label to include pediatric patients 2 years and older
primary humoral immunodeficiency (PI)source ↗
◆Oral PresentationASCENIVApprovedPresentation
Positive, statistically significant real-world ASCENIV outcomes to be presented at CIS in May 2026
primary humoral immunodeficiencysource ↗
▲Quarterly UpdateASCENIVApprovedCorporate
April 2026 demand run-rate in-line with Q1 2026 direct sales
primary humoral immunodeficiencysource ↗
▲Quarterly UpdateASCENIVApprovedCorporate
ASCENIV revenue $97.5M in Q1 2026, 28% YoY growth
primary humoral immunodeficiencysource ↗
▼Quarterly UpdateBIVIGAMApprovedCorporate
BIVIGAM revenue $15.4M in Q1 2026, -54% YoY decline
primary humoral immunodeficiencysource ↗
▼Short Report ActivistCorporate
Culper Research published short report alleging channel stuffing and undisclosed related party distributor
▼Equity OfferingCorporate
ADMA announces $125 million accelerated share repurchase with JPMorgan as part of $200 million 2026 total share repurchase initiative
▲Quarterly UpdateCorporate
Year-end 2025 cash of ~$88 million; unaudited operating cash flow of ~$40 million in Q4 2025
▲Manufacturing MilestoneASCENIVApprovedCMC / Inspection
FDA Lot Release of First Yield-Enhanced Production Batches
primary humoral immunodeficiencysource ↗
▲RWE DataASCENIVApprovedClinical Data
Positive, Statistically Significant Real-World Health Outcomes Demonstrated for ASCENIV
primary humoral immunodeficiencysource ↗
▲Timing GuidancePresentation
Yield-Enhanced Production Efficiencies Expected to Drive Margin Expansion Beginning in 4Q 2025 and Continuing Through 2026
▲Manufacturing MilestoneASCENIVApprovedCMC / Inspection
Initiated commercial-scale manufacturing with FDA-approved yield enhancement process; initial batches delivering 20%+ increase in finished IG output
primary humoral immunodeficiencysource ↗
▲Debt Royalty FinancingCorporate
Secured $300 million syndicated debt refinancing led by J.P. Morgan
▲Manufacturing MilestoneCMC / Inspection
Acquired new Boca Raton operating site to expand cGMP manufacturing space by up to 30% at peak
▲Timing GuidancePresentation
Reaffirmed FY 2025-2026 total revenue, Adjusted EBITDA, and Adjusted Net Income guidance; accelerated growth expected in 2H 2025
▲Equity OfferingCorporate
Repurchased approximately $15 million of common stock during Q2 2025
◆FDA ApprovalASCENIVApprovedFDA Decision
FDA approval of yield enhancement production process anticipated
primary humoral immunodeficiencysource ↗
▲FDA ApprovalFDA Decision
FDA approval of innovative yield enhancement production process
yield enhancement production processsource ↗
◆Oral PresentationPresentation
ADMA Biologics to participate in Raymond James Institutional Investor Conference fireside chat
◆Oral PresentationPresentation
ADMA Biologics presentation at 43rd Annual J.P. Morgan Healthcare Conference
▲Partnership / LicenseCorporate
Execution of 3rd party supply contracts for high titer plasma through late 2030s
▲Partnership / LicenseASCENIVApprovedCorporate
Executed multiple long-term high titer plasma supply contracts for ASCENIV through late 2030s
primary humoral immunodeficiencysource ↗
●NDA SubmissionRegulatory Filing
Prior Approval Supplement (PAS) submitted to FDA for yield enhancement production process
▲Quarterly UpdateCorporate
FY 2025 revenue guidance increased to >$445M, net income >$155M, adjusted EBITDA >$200M
▲Timing GuidancePresentation
Revising FY 2025 Adjusted Net Income Guidance to ~$158M and Raising FY 2026 Adjusted Net Income Guidance to >$255M
◆Preclinical PoCSG-001Preclinical
Expected to establish research protocols for forthcoming animal studies
Streptococcus pneumoniae infectionsource ↗
▲Preclinical PoCSG-001Preclinical
Successful production of pilot-scale batch of SG-001
Streptococcus pneumoniae infectionsource ↗
◆Oral PresentationPresentation
Participation in 2024 Cantor Global Healthcare Conference fireside chat
▲Debt Royalty FinancingCorporate
Partial paydown of $30 million on revolving credit facility with Ares Capital
▲Manufacturing MilestoneCMC / Inspection
Commercial scale production of innovative biologics manufacturing process supports potential yield enhancement of ~20%
Past FDA Catalysts and PDUFA Decisions
How ADMA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2018-12-19 | Bivigam | PDUFA Date CRL | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D26 / 100
Pipeline Score
$0M
Pipeline Value
$2.2B
Commercial Value
Fair Value
Valuation Signal
6
Drugs Scored
-
rNPV / MCap
Top 78%
Small Cap(rank 515 of 660)
Percentile Rank
ADMA Biologics Inc faces pipeline headwinds (26/100), with 6 assets in development.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $512.3M x 4.4 = $2.2B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| ASCENIV | $403M | - | - |
| BIVIGAM | $86M | - | - |
| Plasma Collection Centers | $17M | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every ADMA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ASCENIV Fast Track | Respiratory Syncytial Virus infection | 2019-10-07 | Patient one was discharged from the hospital on hospital day eighty-eight, and currently requires no respiratory support.; Patient two was discharged from the hospital on hospital day six.Read More | ADMA Biologics Announces Data Presented at IDWeek 2019 RAMSEY, N.J. and BOCA RATON, FL.Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kohler TerryOfficer (CFO and Treasurer) | Grant/Award | 85,130 143,149 held | $0.00 | 07/16/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ADMA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0 % (-100 %) | 952.00 K | 113.77 K | -75.65% ( -353.47 K) |
ADMA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ADMA ranks across every disease it competes in
Competitive Position is a premium feature
See how ADMA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialADMA News
ADMABerger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)
Berger Montague PC is investigating the board of directors of ADMA Biologics, Inc. for a possible breach of fiduciary duty. This inquiry raises concerns about the governance practices within the company. Shareholders may be affected by the outcomes of this investigation, which could impact the company's reputation and operations.
Read more →ADMA▲ +8.6%on this news
ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update
ADMA Biologics reported a strong second quarter for 2026, with total revenue of $124.4 million, marking a 2% increase year-over-year. ASCENIV revenue surged by 24% to $102.9 million, driven by higher utilization and physician adoption. The company reiterated its financial guidance for the year, reflecting confidence in sustained growth despite challenges in the BIVIGAM segment.
Read more →ADMAADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026
ADMA Biologics will report its second quarter 2026 financial results on August 5, 2026, after market close. A conference call will follow at 4:30 p.m. ET for management to discuss the results and company updates. ADMA specializes in developing and marketing biologics for immunodeficient patients and operates an FDA-licensed facility.
Read more →ADMAADMA Biologics Investigation: ADMA Biologics (ADMA) Investigated for Alleged Channel Stuffing – Contact BFA Law if You Suffered Losses
ADMA Biologics, Inc. is currently under investigation by Bleichmar Fonti & Auld LLP for potential violations of federal securities laws. The investigation centers around allegations that the company's reported 20% revenue growth in 2025 resulted from a channel stuffing scheme, misleading investors about actual demand. A report from Culper Research claims that without such practices, the company would have experienced a 3% decline in revenue. Following these revelations, the stock price of ADMA Biologics fell sharply by 29%. Investors are encouraged to seek legal options for potential losses.
Read more →ADMA$ADMA Shareholder Announcement: ADMA Biologics may have Misled Investors about its Revenue – Contact BFA Law about its Pending Investigation
ADMA Biologics, Inc. is facing an investigation by Bleichmar Fonti & Auld LLP for potential violations of federal securities laws. The inquiry follows allegations that the company engaged in channel stuffing to inflate its reported revenue growth for 2025. Research by Culper Research indicated that ADMA's actual growth was only a -3% decline rather than the 20% growth reported, leading to a significant drop in its stock price after the disclosures. Investors in ADMA Biologics are encouraged to seek legal counsel regarding their options.
Read more →ADMAADMA Inquiry News: ADMA Biologics Investors are Notified of BFA Law’s Ongoing Investigation into the Company’s Potential Misstatements – Contact the Firm if You Lost Money
ADMA Biologics is facing scrutiny from Bleichmar Fonti & Auld LLP over allegations of securities fraud, specifically related to inflating revenue figures through questionable practices, such as channel stuffing. A recent report by Culper Research suggests that the company's claimed 20% revenue growth for 2025 was misleading, indicating a potential revenue decline instead. The investigation has led to a significant decline in ADMA's stock price, falling 29% after the report was published. Investors who may have incurred losses are encouraged to seek further information on legal options.
Read more →ADMA▼ -16%on this newsshared move
ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
ADMA Biologics reported its first quarter 2026 financial results, revealing total revenue of $114.5 million, which remained flat year-over-year. ASCENIV revenue saw a 28% increase, while BIVIGAM experienced a significant decline. The company expressed confidence in ASCENIV's growth outlook despite competitive pressures affecting overall market dynamics. Adjusted Net Income and EBITDA both showed substantial year-over-year growth.
Read more →ADMAADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older
ADMA Biologics has received FDA approval to expand the label for ASCENIV to include pediatric patients aged two years and older with primary humoral immunodeficiency. This approval allows for earlier treatment of younger patients and reflects the successful completion of required clinical trials. The company aims to enhance the utilization of ASCENIV as a treatment option for immune compromised children.
Read more →ADMA$ADMA Stock Drop Alert: ADMA Biologics Stock Plummeted 29% on News of Channel Stuffing – Investors Notified to Contact BFA Law about its Investigation
ADMA Biologics is facing an investigation by Bleichmar Fonti & Auld LLP for potential violations of federal securities laws stemming from allegations of channel stuffing. A report by Culper Research claims that the company misrepresented a 20% revenue growth in 2025, which was allegedly achieved through techniques like incentivizing distributors to stock excess product. As a result of the negative news, the company's stock price plummeted 29% over two trading days. Investors are being notified of potential legal actions as a consequence of these findings.
Read more →ADMAADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026
ADMA Biologics, Inc. announced it will report its first quarter 2026 financial results on May 6, 2026. The company will host a live conference call at 4:30 p.m. ET to discuss these results and provide updates. ADMA specializes in manufacturing and marketing specialty biologics for immunodeficient patients.
Read more →ADMA$ADMA Fraud: ADMA Biologics Channel Stuffing Claims Trigger Securities Investigation – Investors Alerted to Contact BFA Law
ADMA Biologics, Inc. is currently facing a securities investigation led by Bleichmar Fonti & Auld LLP due to allegations of channel stuffing that allegedly inflated the company's reported revenue growth of 20% in 2025. According to a report from Culper Research, the actual growth could have been a decline of 3% had the company not engaged in these practices. As a result, ADMA's stock price fell by 29% shortly after the report was published, reflecting investor concerns over the legitimacy of its financial disclosures.
Read more →ADMAADMA Biologics (NASDAQ: ADMA) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.
ADMA Biologics is currently being investigated by Lowey Dannenberg P.C. for possible breaches of federal securities laws. The investigation follows a report by Culper Research, which accused ADMA of channel stuffing practices to inflate revenue figures inaccurately. Specifically, the report claims the company's inducement of a distributor to stockpile excess ASCENIV led to misleading financial statements, potentially showing a growth that was not genuinely realized. The law firm is looking into whether ADMA provided its investors with truthful and complete information regarding its financial status.
Read more →ADMA$ADMA Legal News: ADMA Biologics Investors may have been Affected by Fraud after Channel Stuffing Claims Disclosed – Contact BFA Law if You Lost Money
ADMA Biologics is under investigation by Bleichmar Fonti & Auld LLP for potential federal securities law violations related to alleged channel stuffing to artificial growth in reported revenues. A report by Culper Research claims that the company induced a distributor to stock excess products, inflating revenue figures. Following these claims, ADMA's stock experienced a significant decline of 29% over two trading days. Investors who feel impacted by these developments are encouraged to seek legal advice and possibly join a class action lawsuit.
Read more →ADMA▲ +11.6%on this newsshared move
ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research
ADMA Biologics has issued a statement refuting allegations made by short seller Culper Research regarding its product ASCENIV. The company asserts that demand for ASCENIV is increasing and that its inventory levels are consistent with industry standards. ADMA also emphasizes that the allegations reflect a misunderstanding of its business model and the IVIG market dynamics.
Read more →ADMA▼ -15%on this news· ran to -27% by day 1shared move
ADMA Biologics Addresses Misleading Short-Seller Report
ADMA Biologics has responded to a misleading report from Culper Research, which holds a short position in the company. The report is criticized for being based on unreliable sources and containing false statements. ADMA reaffirms its commitment to transparency and compliance with financial reporting standards. The company continues to focus on developing specialty biologics for immunodeficient patients.
Read more →ADMA▲ +6.5%on this news
ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative
ADMA Biologics has announced a $125 million accelerated share repurchase agreement with JPMorgan as part of a broader $200 million capital return initiative planned for 2026. This move reflects the company's strong financial health and confidence in its growth trajectory. ADMA aims to enhance shareholder value while continuing to invest in strategic growth initiatives.
Read more →ADMAADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
ADMA Biologics reported record financial results for FY 2025, with total revenue reaching $510 million, a 20% increase from the previous year. The company highlighted strong growth in ASCENIV sales, which rose by 51%. Despite a decrease in GAAP net income attributed to a prior year's tax benefit, adjusted net income and EBITDA showed significant growth. ADMA is optimistic about future revenue growth and operational improvements.
Read more →ADMAADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
ADMA Biologics, Inc. will announce its fourth quarter and full year 2025 financial results on February 25, 2026. The company will host a live conference call at 4:30 p.m. ET to discuss these results and provide additional updates. ADMA specializes in developing biologics for immunodeficient patients and has several FDA-approved products.
Read more →ADMAADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update
ADMA Biologics has announced preliminary unaudited total revenue for FY 2025 of approximately $510-511 million, which meets or exceeds previous guidance. The company reported an estimated operating cash flow of around $40 million for Q4 2025 and had cash holdings of approximately $88 million at year-end. Looking ahead, ADMA anticipates the first full year of yield-enhanced production in 2026, and the rollout of ASCENIV data is expected to further bolster growth. ADMA also reiterated its financial targets for FY 2026 and FY 2027, projecting substantial increase in revenue and adjusted EBITDA.
Read more →About ADMA Biologics Inc
HeadquartersC/O ADMA BIOLOGICS, INC., RAMSEY, NJ, 07446
Founded2004
BIOPHARMAWATCH ELITE PLUS
Trade the next ADMA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime